Changes to the QTdrugs List and List of Drugs to Avoid in CLQTS

December 2, 2024

Re: Changes to the QTdrugs List and List of Drugs to Avoid in CLQTS

AZCERT's Scientific Review Committee has found substantial evidence that Opipramol (antidepressant), Revumenib (anticancer) and Sitafloxacin (antibiotic) are associated with the development of QT prolongation but lack convincing evidence of causing torsades de pointes (TdP). Therefore, these drugs have been added to the Possible Risk of TdP category (PR) and to the List of Drugs to Avoid in patients with Congenital Long QT Syndrome (DTA List).

The Committee also reviewed newly available evidence for the anticonvulsant Levetiracetam and have removed it from the PR risk category of the QTdrugs List and from the List of Drugs to Avoid in CLQTS.

As demonstrated by these revisions, the QTdrugs List and the DTA are dynamic and change regularly in response to changes in the scientific evidence that is available. To perform a quick search of the most current versions of the Lists we recommend using the CredibleMeds website or one of the available smartphone apps (Apple or Android)

AZCERT Scientific Review Committee